phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

ASCO: Targeted Therapy Combo Nearly Doubles Time Without Disease Progression for Patients with Advanced Colorectal Cancer

Updated results from the Phase 3 BREAKWATER trial, led by researchers at The University of Texas MD Anderson Cancer Center, demonstrated a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination.

June 1, 2026


June 11 2026

June 10 2026

June 9 2026

June 8 2026

June 7 2026

June 5 2026

June 4 2026

June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy